Credit Suisse analyst Vamil Divan maintained a Buy rating on Johnson & Johnson (NYSE: JNJ) today and set a price target of $149. The company’s shares opened today at $136.56.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.6% and a 46.3% success rate. Divan covers the Healthcare sector, focusing on stocks such as Aimmune Therapeutics, Merck & Company, and Portola Pharma.
Currently, the analyst consensus on Johnson & Johnson is a Strong Buy with an average price target of $154, which is a 12.8% upside from current levels. In a report released yesterday, Wells Fargo also reiterated a Buy rating on the stock with a $160 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $148.32 and a one-year low of $118.62. Currently, Johnson & Johnson has an average volume of 6.17M.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
